Skip to main content
. 2022 Mar 29;12(3):e056159. doi: 10.1136/bmjopen-2021-056159

Table 1.

Blood-based biomarkers assessed in MIRNA

Parameter Biomarker
Liver function tests

  • Alanine aminotransferase

  • Aspartate aminotransferase

  • Alkaline phosphatase

  • γ-glutamyl transferase

  • Total bilirubin
NASH-related

  • 3-parameter derived enhanced liver fibrosisTM score (marker of liver fibrosis used to track disease progression)

  • Cytokeratin-18-M30 fragment (marker of apoptotic activity)

  • Cytokeratin-18-M65 fragment (marker of necrotic activity)

  • N-terminal propeptide of procollagen type III (marker of fibrinogenesis)

  • C-terminal fragment of α3 chain of procollagen type VI (marker of fibrinolysis)
Fasting lipid parameters/markers of target engagement

  • Fasting serum lipid panel:

    • Total cholesterol

    • Triglycerides

    • High density lipoprotein cholesterol

    • Direct low density lipoprotein cholesterol

    • Direct very low density lipoprotein cholesterol

  • Fasting serum apolipoproteins:

    • A1

    • Btotal

    • B100

    • B48

    • C3

    • E

  • High-sensitivity C-reactive protein

  • Proprotein convertase subtilisin/kexin type 9
Glycaemic

  • HbA1c

  • Fasting plasma glucose

  • Fasting plasma insulin

  • Homeostatic model assessment of insulin resistance

  • Adiponectin

Additional samples collected for exploratory biomarker analysis are listed in online supplemental table 4.

HbA1c, glycated haemoglobin; MIRNA, Metabolic Interventions to Resolve NASH with fibrosis; NASH, non-alcoholic steatohepatitis.